Source Articles
mTOR
Showing 4 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 1 | 62 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | mTOR | Everolimus | — | Missing | intra-cranial | brain | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 1 | Missing | G3 or higher: 1 pt | — | — |
| Franzese et al. | 2021 | Retrospective | The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group | 10.1007/s10585-021-10131-w | — | 2 | Missing | Kidney cancer | oligometastatic | mTOR | Everolimus, Temsirolimus | — | Missing | extra-cranial | lung, liver, adrenal gland, bone, muscle, LN unspecified, other | Renal bed, Pancreas | 36 | 10 | 75 | 5 | 1 | 10 | Missing | Missing | Missing | Treatment-rel. | 0 | 0 | 0 | 0 | 0 | — | — |
| Kroeze et al. | 2021 | Retrospective | Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma | 10.1111/bju.15284 | — | 4 | 61 | Kidney cancer | metastatic | mTOR | Everolimus, Temsirolimus | — | 128 | any | brain, lung, liver, bone, LN unspecified, other | soft tissue | Missing | Missing | Missing | Missing | 1 | 10 | Missing | Missing | Missing | RT-related | 1 | 1 | — | acute G3: 2 AE, late G3: 1 AE | acute G3: 1 pt, late G3: 1 pt | acute G3: headache, vertigo., late G3: dysphasia by radiation necrosis | — |
| Dengina et al. | 2019 | Prospective | Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study | 10.1136/esmoopen-2019-000535 | NCT02864615 | 4 | 54.5 | Kidney cancer | any | mTOR | Everolimus, Temsirolimus | — | 4 | extra-cranial | lung, liver, bone, LN unspecified, other | kidney | Missing | Missing | Missing | Missing | Missing | Missing | Missing | Missing | Missing | Treatment-rel. | — | — | 0 | 0 | 0 | — | — |